Nearly 40 years after HIV was first identified, the virus continues its devastating march across the globe. Today, 38 million people live with HIV, and each year brings 1.5 million new infections and ...
For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Investor's Business Daily on MSN
Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot
Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...
Ten years ago, the Indiana community of Austin made headlines for its historic HIV outbreak brought on by intravenous drug ...
Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback